We explored the relative merits of employing CD25-biased versus CD25-blocking anti-IL-2 antibodies, revealing the unexpected therapeutic advantage for CD25-biased anti-IL-2 antibodies in the context of ICI combination therapy for cancer treatment. This evidence concerns the gene IL2RA and cancer.